Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Renal Cell 3Fallopian Tube Neoplasms 2Colorectal Neoplasms 2Triple Negative Breast Neoplasms 1Solid Tumors 1Sarcoma 1Recurrence 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Liver Neoplasms 1Glioblastoma 1Gastrointestinal Neoplasms 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms 1Advanced Adult Hepatocellular Carcinoma 1

Interventions

Oxaliplatin 4Leucovorin 4Irinotecan 4Fluorouracil 4Capecitabine 3Bevacizumab 3cobimetinib 2Tomography, X-Ray Computed 2Surveys and Questionnaires 2Standard of Care 2Specimen Handling 2Panitumumab 2Magnetic Resonance Spectroscopy 2Ketamine 2Hydroxychloroquine 2Cyclophosphamide 2Cisplatin 2ulixertinib 1trifluridine tipiracil drug combination 1trastuzumab deruxtecan 1tivozanib 1sodium thiosulfate 1rucaparib 1romiplostim 1rilotumumab 1regorafenib 1pralsetinib 1ponatinib 1pembrolizumab 1osimertinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Gastrointestinal Neoplasms × tivozanib × Clear all
NCT01058655 2017-04-13

RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer

Dana-Farber Cancer Institute

Phase 1/2 Completed
56 enrolled 15 charts
Gastrointestinal

Gastrointestinal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡